Medical-device firms have transitioned quality documentation toward the effective QMSR and ISO 13485:2016 alignment. The mandate becomes urgent when an audit, regulatory change, incident or assurance request requires the organisation to prove how an obligation operates in practice.
Requirement, process, control, record and CAPA traceability remains incomplete or manual. The structural gap is the absence of traceability from obligation through process, owner, system, control, execution and retained evidence.
Medical-device manufacturers must operate under the FDA QMSR, effective 2 February 2026, incorporating ISO 13485:2016 by reference. Across the enterprise, assurance remains periodic and manual while operational change creates new gaps faster than review cycles can find them.
Build an inspection-ready requirement-to-process model with controlled remediation. This enables a leadership team to act because change and assurance can be managed as connected operational work, with accountable remediation and evidence available by design.
- Faster gap closure, reduced inspection preparation and stronger QMS confidence
- Faster regulatory impact assessment
- Earlier detection of control and evidence gaps
- Reduced audit and inspection preparation
- Defensible traceability from duty to execution
The FDA QMSR became effective on 2 February 2026 and incorporates ISO 13485:2016 by reference into device quality-system requirements.
FDA: Quality Management System Regulation
FDA confirms that the revised 21 CFR Part 820 QMSR became effective on 2 February 2026 and introduced an updated medical-device inspection approach.
FDA: QMSR Frequently Asked Questions